Straumann Holding AGXSWX:STMN -0.42%98 Return-on-Tangible-Equity is 19.24% as of Dec. 2025, which is 61% below its 10-year median of 48.74. GuruFocus rates XSWX:STMN with a GF Score™ of 98/100 and a GF Value™ of CHF136.92 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Straumann Holding AG ranks better than 88.65% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Straumann Holding AG's annualized net income for the quarter that ended in Dec. 2025 was CHF239 Mil. Straumann Holding AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was CHF1,242 Mil. Therefore, Straumann Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 19.24%.
The historical rank and industry rank for Straumann Holding AG's Return-on-Tangible-Equity or its related term are showing as below:
XSWX:STMN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 15.54 Med: 48.74 Max: 74.64
Current: 29.5
During the past 13 years, Straumann Holding AG's highest Return-on-Tangible-Equity was 74.64%. The lowest was 15.54%. And the median was 48.74%.
XSWX:STMN's Return-on-Tangible-Equity is ranked better than 88.65% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs XSWX:STMN: 29.50
Straumann Holding AG (XSWX:STMN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Straumann Holding AG Return-on-Tangible-Equity Related Terms
Straumann Holding AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG Return-on-Tangible-Equity Chart
XSWX:STMN vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.24% mean?
Straumann Holding AG (XSWX:STMN) has a Return-on-Tangible-Equity of 19.24% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Straumann Holding AG and its competitors. This is 61% below median its historical median of 48.74. Over the past decade, Straumann Holding AG's Return-on-Tangible-Equity has ranged from 15.54 to 74.64. According to the industry distribution chart, Straumann Holding AG ranks #86 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 11.3%.
Is Straumann Holding AG's Return-on-Tangible-Equity too high?
Straumann Holding AG's current Return-on-Tangible-Equity of 19.24% is 61% below median its 10-year median of 48.74. Over the past 10 years, this metric has ranged from a low of 15.54 to a high of 74.64. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Straumann Holding AG's value of 19.24% is 371.6% above this industry median. Based on the distribution chart, Straumann Holding AG ranks #86 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Straumann Holding AG has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #86 out of 758 companies for Return-on-Tangible-Equity. This places Straumann Holding AG in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.08. Straumann Holding AG's value of 19.24% is 371.6% above this benchmark. Historically, Straumann Holding AG's own Return-on-Tangible-Equity has ranged from 15.54 to 74.64 over the past decade. While the company's 10-year median is 48.74 vs. the industry median of 4.08, Straumann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current Return-on-Tangible-Equity of 19.24% is 371.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Return-on-Tangible-Equity is 19.24%, which is 61% below median its own 10-year median of 48.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF136.92, compared to a current price of CHF106.35 — trading 22.3% below its estimated fair value. The current Return-on-Tangible-Equity is 19.24%, which is 61% below median its 10-year median of 48.74 and 371.6% above the Medical Devices & Instruments industry median of 4.08. Straumann Holding AG's overall GF Score™ is 98/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Return-on-Tangible-Equity is 19.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF106.35 is trading 22.3% below its estimated GF Value™ of CHF136.92.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Return-on-Tangible-Equity: 19.24% (61% below median its 10-year median of 48.74)
GF Value™: CHF136.92 vs. price of CHF106.35 (22.3% below fair value)
Industry Position: 371.6% above the Medical Devices & Instruments median (#86 of 758)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
98GF Score
Get the complete analysis for XSWX:STMN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
